which was revised to Rs 77.81 crores in 1990, against which M/s. Hoechst filed Writ Petition in Bombay Court. The Bombay Court framed a time bound schedule for finalising the liability. giving the hearing to the company and passing a final speaking order. The company has been given last and final opportunity to submit the requisite data. In case full data is not given by the company whatever data becomes available to the Government from whichever source, will be made use of to supplement the company's data. After the liability has been tentatively determined in this way. the company will be givtn a hearing in accordance with the Bombay High Court's Order and a Speaking Order will be passed hereafter, M/s. Hoechst has made a payment of Rs. 3.12 crores against their liabilities.

As regards M/s. Carews, it came to notice of Government that this company was manufacturing and marketing Combiflam tablets through M/s. Roussel Pharmaceutical without price approval under DPCO, 1979 as will as DPCO, 1987. It was noted that the company was overcharging in the price of Combiflam tablets between the period November, 1986 to August, 1989. A tentative liability of 7.11 crores has been calculated aaginst this company for the period November, 1986 to December, 1988. This amount was communicated to the company with the advice to deposit the same with the Government and details pertaining to the remaining period were also called for to work out the total liability. The company filed 3 Writ Petitions in Calcutta High Court, which are, at present, pending in the Calcutta High Court.

Recoveries to be made from M/s. Merck India Ltd.

3085. SHRI SANTOSH KUMAR SAHU: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M/s. E. Merck India Ltd. is followed as leader price for Ibuprofen 400 Mg and Paracotamol 325 Mg. combination;

(b) whether any demand has been raised on the company for recovering of amount overcharged from November, 1986 to December, 1988; and

(c) if not, the reasons to which Government have not initiated any proceedings against the company?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) No, Sir.

(c) *Prima facie*, there appears to be no case of overcharging against the company. However, Government is yet to take a final view in the matter.

Furnishing of details of imports by Multinational Companies

3086. MISS SAROJ KHAPARDE: Will the PRIME MINISTER be pleased to state:

(a) whether Government have directed the Indian offshots of Multinational companies to furnish the details of the products they import from their overseas parent companies and associate companies; and

(b) if so, what are the details in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Attention of drug companies has been invited through industry associations to para 6.7 of the "Measures for Rationalisation Quality Control and Growth of Pharmaceutical Industry in India" announced by the Government in December, 1986 requesting them to furnish the following details:—

1. List of bulk drugs manufactured by the company.

2. Details of intermediates and other raw materials imported by the company from their principals or their associated companies for manufacture of each bulk drug since January 1987, yearwise,